CLEC5A and adult-onset Still disease: Our longitudinal follow-ups of AOSD patients showed a significant decrease in the levels of circulating CLEC5A-expressing monocytes and granulocytes after 6 months of therapy, paralleling the clinical remission (Figure 5).